TejasPatilMD

Physician

Dr. Patil is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
12801 E 17th Ave FL 81018
Aurora, CO 80045
Phone+1 303-724-9238

Fax+1 303-724-3889

A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer Start of enrollment: 2021 Mar 08
Recruiting
Phase 1, Phase 2
Roles: Principal Investigator

PubMed

305 citations
Management of Brain Metastases in Tyrosine Kinase Inhibitor–Naïve Epidermal Growth Factor Receptor–Mutant Non–Small-Cell Lung Cancer: A Retrospective Multi-Institution...
William J. Magnuson, Nataniel H. Lester-Coll, Abraham J. Wu, T. Jonathan Yang, Natalie A. Lockney
Journal of Clinical Oncology. 2017-01-23
160 citations
NCCN Guidelines® Insights: Non-Small Cell Lung Cancer, Version 2.2023.
David S Ettinger, Douglas E Wood, Dara L Aisner, Wallace Akerley, Jessica R Bauman
Journal of the National Comprehensive Cancer Network. 2023-04-01
64 citations
Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1 inhibitors in patients with onc...
Terry L. Ng, Yiwei Liu, Anastasios Dimou, Tejas Patil, Dara L. Aisner
Cancer. 2019-04-01

Lectures

Clinicopathologic profile and treatment outcomes of non-sensitizing EGFR and HER2 (ERBB2) activating mutations in NSCLC: Results from a single-center retrospective study.
2019 ASCO Annual Meeting - 6/1/2019

‘A Way of Embodying Hope’: 5-Year Lung Cancer Survivors CelebrateMay 13th, 2024
How the Immune System Affects Drug Response in Lung Cancer PatientsMay 10th, 2024
Taking Aim at MET and KRAS in NSCLCOctober 31st, 2022
Join now to see all